Brian Slomovitz, MD, Discusses Previous Trials of Pembrolizumab in Endometrial Cancer

Brian Slomovitz, MD, spoke about previously conducted trials that used regimens involving pembrolizumab and chemotherapy for patients with newly diagnosed high-risk endometrial cancer at SGO 2022.

During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Brian Slomovitz, MD, leader of endometrial trial for the Gynecologic Oncology Group (GOG) Foundation, and a gynecologic oncologist at Mount Sinai Medical Center in Miami Beach, Florida, about the trials previously conducted that highlight the same regimen used in the current ongoing phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial (NCT04634877) of adjuvant pembrolizumab (Keytruda) plus chemotherapy with or without radiation therapy. Before the inception of this trial, he said the investigators looked to other trials involving immunotherapy for use across settings in endometrial cancer.

Transcript:

When we designed this trial, we not only looked at this patient population, but we wanted to borrow from some of the ideas and from studies that we were running in later-line trials. In the first-line [metastatic setting], randomized phase 3 trials, we have several studies that [have looked at] at chemotherapy plus or minus immune checkpoint inhibition, starting off with the NRG trial-GY018 trial [NCT03914612] run by Ramez Eskander, MD, it is looking at chemotherapy plus or minus pembrolizumab.

We have a trial that’s also being run through the GOG [Gynecologic Oncology Group] which is called RUBY [NCT03981796], which is looking at the combination of chemotherapy plus or minus the checkpoint inhibitor dostarlimab [Jemperli]. In RUBY Part 2, we’re also looking at chemotherapy, dostarlimab, and niraparib [Zejula]. We have DUO-E/GOG-3041/ENGOT-EN10 [NCT04269200],a GOG and ENGOT [European Network of Gynecological Oncological Trial Groups] trial, looking at the combination of chemotherapy plus or minus their checkpoint inhibitor durvalumab [Imfinzi], and their PARP inhibitor olaparib [Lynparza].

There’s the AtTEnd trial [NCT03603184], which is looking at the Genentech product, atezolizumab [Tecentriq]. The most intriguing [trial] is something called LEAP-001 [NCT03884101], a Merck-sponsored trial looking really to eliminate chemotherapy in all patients with endometrial cancer. It’s pembrolizumab and lenvatnib [Lenvima] versus carboplatin and paclitaxel in the first-line [metastatic] setting. Finally, we have 1 more trial in the first-line setting in MSI [microsatellite instable]–-high patients. This is a study that I’m fortunate to be the global lead on run through GOG and ENGOT in MSI-high patients [treated with] pembrolizumab versus chemotherapy in another way to hopefully eliminate chemotherapy, at least in the first-line management of this disease.

Reference

Slomovitz B, Mirza MR, Lortholary A, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: a phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed high-risk endometrial cancer. Presented at: Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer. March 18-21, 2022. Phoenix, AZ. Poster 570.